Xiuli Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiuli Zhang has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Harvest F. Gu
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
6 shared publications Qijun Wan
Department of Nephrolog, The First Affiliated Hospital of Shenzhen University (Shenzhen Second People's Hospital), Shenzhen, China
3 shared publicationsQinghui Zhou
Department of Nephrolog, The First Affiliated Hospital of Shenzhen University (Shenzhen Second People's Hospital), Shenzhen, China
3 shared publicationsRui Xue
Department of Nephrolog, The First Affiliated Hospital of Shenzhen University (Shenzhen Second People's Hospital), Shenzhen, China
3 shared publicationsTingwen Guan
Department of Pathophysiology, China Medical University, Shenyang, Liaoning Province 110001, PR China
3 shared publicationsZhihong Chi
Department of Pathophysiology, China Medical University, Shenyang, Liaoning Province, 110001, People’s Republic of China
3 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Concurrent κ light chain proximal tubulopathy and crystal-storing histiocytosis in monoclonal gammopathy of renal significance: a rare case report with 4-year follow-up and literature review
Background: Light chain proximal tubulopathy (LCPT) and crystal-storing histiocytosis (CSH) are rare forms of monoclonal immunoglobulin-associated kidney disease, representing either variants of monoclonal gammopathy of renal significance (MGRS) or renal complications of multiple myeloma (MM). Concurrent LCPT and suspected CSH associated with κ light chain MGRS is exceptionally rare, with only three comparable cases reported worldwide. This CARE guideline-compliant report describes the clinical, laboratory and histopathological features of this rare dual renal lesion. Case presentation: A 61-year-old Chinese woman presented with Fanconi syndrome (FS), chronic kidney disease (CKD) and isolated tubular proteinuria. Serum and urine immunofixation electrophoresis showed elevated monoclonal IgGκ. Bone marrow examination revealed mild plasmacytosis (< 10%), with no hypercalcemia, myeloma bone lesions, cast nephropathy or SLiM criteria-defined myeloma events, confirming MGRS and excluding MM and smoldering multiple myeloma (SMM). Diagnostic assessment: Renal biopsy electron microscopy demonstrated dense crystalline inclusions in proximal tubular epithelial cells and interstitial histiocytes. Immunohistochemistry and immunoelectron microscopy confirmed strong κ light chain restriction. These findings are highly suggestive of concurrent LCPT and crystal-storing histiocytosis (CSH). However, definitive confirmation of CSH by CD68 immunohistochemistry—the gold standard for histiocytic lineage identification—could not be performed due to exhaustion of the limited archival biopsy tissue. This case is therefore reported as “CSH suspected based on ultrastructural and immunoelectron microscopy criteria. Intervention and outcome: The patient received first-line CyBorD (cyclophosphamide, bortezomib, and dexamethasone) chemotherapy, achieving partial hematological remission (PR) and marked improvement of Fanconi syndrome. Renal function remained normal and stable throughout the 48-month follow-up period. Conclusions: We report this rare κ light chain MGRS case with concurrent LCPT and suspected CSH, which showed favorable responses to CyBorD with durable renal stability. This case highlights integrated diagnostic strategies and boosts clinical awareness of this rare monoclonal gammopathy-related renal injury.
- 15 July 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessConcurrent κ light chain proximal tubulopathy and crystal-storing histiocytosis in monoclonal gammopathy of renal significance: a rare case report with 4-year follow-up and literature review
Background: Light chain proximal tubulopathy (LCPT) and crystal-storing histiocytosis (CSH) are rare forms of monoclonal immunoglobulin-associated kidney disease, representing either variants of monoclonal gammopathy of renal significance (MGRS) or renal complications of multiple myeloma (MM). Concurrent LCPT and suspected CSH associated with κ light chain MGRS is exceptionally rare, with only three comparable cases reported worldwide. This CARE guideline-compliant report describes the clinical, laboratory and histopathological features of this rare dual renal lesion. Case presentation: A 61-year-old Chinese woman presented with Fanconi syndrome (FS), chronic kidney disease (CKD) and isolated tubular proteinuria. Serum and urine immunofixation electrophoresis showed elevated monoclonal IgGκ. Bone marrow examination revealed mild plasmacytosis (< 10%), with no hypercalcemia, myeloma bone lesions, cast nephropathy or SLiM criteria-defined myeloma events, confirming MGRS and excluding MM and smoldering multiple myeloma (SMM). Diagnostic assessment: Renal biopsy electron microscopy demonstrated dense crystalline inclusions in proximal tubular epithelial cells and interstitial histiocytes. Immunohistochemistry and immunoelectron microscopy confirmed strong κ light chain restriction. These findings are highly suggestive of concurrent LCPT and crystal-storing histiocytosis (CSH). However, definitive confirmation of CSH by CD68 immunohistochemistry—the gold standard for histiocytic lineage identification—could not be performed due to exhaustion of the limited archival biopsy tissue. This case is therefore reported as “CSH suspected based on ultrastructural and immunoelectron microscopy criteria. Intervention and outcome: The patient received first-line CyBorD (cyclophosphamide, bortezomib, and dexamethasone) chemotherapy, achieving partial hematological remission (PR) and marked improvement of Fanconi syndrome. Renal function remained normal and stable throughout the 48-month follow-up period. Conclusions: We report this rare κ light chain MGRS case with concurrent LCPT and suspected CSH, which showed favorable responses to CyBorD with durable renal stability. This case highlights integrated diagnostic strategies and boosts clinical awareness of this rare monoclonal gammopathy-related renal injury.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-12
SLC30A8 Promoter Hypomethylation is Associated with Impaired Renal Function in Type 2 Diabetes: A Cross-Sectional Study
Background: Diabetic kidney disease (DKD) remains a major challenge in type 2 diabetes (T2DM) management. The solute carrier family 30 member 8 (SLC30A8) gene is a known T2DM susceptibility locus. However,the relationship between SLC30A8 promoter methylation and renal function in DKD remains unclear. This study aimed to investigate this association. Methods: In this cross-sectional study, 351 hospitalized patients with T2DM (181 with DKD, 170 without) were enrolled. Peripheral blood DNA methylation at six CpG sites in the SLC30A8 promoter was quantified by pyrosequencing. Multivariate linear/logistic regression, smooth curve fitting, and subgroup analyses were used to evaluate the independent association between SLC30A8 methylation and estimated glomerular filtration rate (eGFR). Results: SLC30A8 methylation was significantly lower in the DKD group (73.6% ± 6.4%) than in the T2DM-only group (88.7% ± 7.1%, P < 0.001), and progressively decreased across categories of declining eGFR and increasing albuminuria (all P for trend < 0.05). In a multivariate linear regression model adjusted for age, sex, BMI, systolic blood pressure, UACR, uric acid, lipids, fasting glucose, and diabetes duration, each 1% increase in methylation was independently associated with a 2.336 mL/min/1.73 m2 higher eGFR (95% CI: 1.780– 2.891, P < 0.001). A nonlinear threshold was identified at 70.9% methylation. Below this, the association with eGFR was nonsignificant; above it, each 1% increase correlated with a 4.471 mL/min/1.73 m2 increase in eGFR (95% CI: 3.961– 4.981, P < 0.001). This stable association was consistent across all clinical subgroups (P for interaction > 0.05). Conclusion: SLC30A8 promoter hypomethylation is independently associated with impaired renal function in T2DM, exhibiting a dose-response relationship where lower methylation levels correlated with more severe kidney damage, and a distinct threshold effect at approximately 70.9% methylation, below which the association with eGFR was significantly stronger. These exploratory findings suggest that SLC30A8 promoter methylation may represent a promising epigenetic biomarker for DKD risk stratification, warranting further validation in prospective studies.
- 1 May 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-12
Open AccessSLC30A8 Promoter Hypomethylation is Associated with Impaired Renal Function in Type 2 Diabetes: A Cross-Sectional Study
Background: Diabetic kidney disease (DKD) remains a major challenge in type 2 diabetes (T2DM) management. The solute carrier family 30 member 8 (SLC30A8) gene is a known T2DM susceptibility locus. However,the relationship between SLC30A8 promoter methylation and renal function in DKD remains unclear. This study aimed to investigate this association. Methods: In this cross-sectional study, 351 hospitalized patients with T2DM (181 with DKD, 170 without) were enrolled. Peripheral blood DNA methylation at six CpG sites in the SLC30A8 promoter was quantified by pyrosequencing. Multivariate linear/logistic regression, smooth curve fitting, and subgroup analyses were used to evaluate the independent association between SLC30A8 methylation and estimated glomerular filtration rate (eGFR). Results: SLC30A8 methylation was significantly lower in the DKD group (73.6% ± 6.4%) than in the T2DM-only group (88.7% ± 7.1%, P < 0.001), and progressively decreased across categories of declining eGFR and increasing albuminuria (all P for trend < 0.05). In a multivariate linear regression model adjusted for age, sex, BMI, systolic blood pressure, UACR, uric acid, lipids, fasting glucose, and diabetes duration, each 1% increase in methylation was independently associated with a 2.336 mL/min/1.73 m2 higher eGFR (95% CI: 1.780– 2.891, P < 0.001). A nonlinear threshold was identified at 70.9% methylation. Below this, the association with eGFR was nonsignificant; above it, each 1% increase correlated with a 4.471 mL/min/1.73 m2 increase in eGFR (95% CI: 3.961– 4.981, P < 0.001). This stable association was consistent across all clinical subgroups (P for interaction > 0.05). Conclusion: SLC30A8 promoter hypomethylation is independently associated with impaired renal function in T2DM, exhibiting a dose-response relationship where lower methylation levels correlated with more severe kidney damage, and a distinct threshold effect at approximately 70.9% methylation, below which the association with eGFR was significantly stronger. These exploratory findings suggest that SLC30A8 promoter methylation may represent a promising epigenetic biomarker for DKD risk stratification, warranting further validation in prospective studies.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Artemether Attenuates High Glucose‐Induced Inflammation and Fibrogenesis in Renal Tubular Epithelial Cells by Modulating the TGF‐ β /Smad Pathway Via PPAR γ Activation
Artemether (Art) is a derivative of artemisinin, originally sourced from traditional Chinese herbal medicine, with improved bioavailability, and is widely used for malaria treatment. Recently, its potential effects on diabetic complications, particularly diabetic kidney disease (DKD), have attracted increasing attention. This study aimed to evaluate the therapeutic effects of Art on DKD and to explore the underlying mechanisms. Specifically, we investigated the protective role of Art against high glucose (HG)‐induced inflammatory biomarkers (transforming growth factor‐ β 1 [TGF‐ β 1], tumor necrosis factor‐ α [TNF‐ α ], interleukin‐1 β [IL‐1 β ], and interleukin‐6 [IL‐6]) and fibrosis in human renal proximal tubular epithelial (HK‐2) cells, focusing on the involvement of peroxisome proliferator‐activated receptor gamma (PPAR γ ) in DKD. To mimic diabetic conditions, HK‐2 cells were exposed to HG (30 mM) to induce inflammation and fibrosis. The therapeutic effects of Art (100 and 200 μ m) were assessed by immunofluorescence, real‐time RT‐PCR, and Western blot analyses. Our results demonstrated that Art effectively reversed the HG‐induced upregulation of inflammatory and fibrogenic markers in HK‐2 cells (∗ p < 0.05, ∗∗ p < 0.001, and ## p < 0.001). Additionally, Art pretreatment restored the HG‐suppressed expression of PPAR γ (∗ p < 0.05 and ## p < 0.001), suggesting that Art exerts its antifibrotic effects by modulating PPAR γ and inhibiting the TGF‐ β /Smad pathway. This hypothesis was further supported by siRNA‐mediated knockdown of PPAR γ , which significantly diminished Art′s antifibrotic effects (∗ p < 0.05, ∗∗ p < 0.001, and ## p < 0.001). In conclusion, our study indicates that Art protects renal tubular epithelial cells by partially modulating PPAR γ ‐dependent inhibition of the TGF‐ β /Smad pathway, thereby mitigating HG‐induced inflammation and fibrosis. These findings suggest that Art holds promising therapeutic potential for DKD treatment.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1)
Open AccessArtemether Attenuates High Glucose‐Induced Inflammation and Fibrogenesis in Renal Tubular Epithelial Cells by Modulating the TGF‐ β /Smad Pathway Via PPAR γ Activation
Artemether (Art) is a derivative of artemisinin, originally sourced from traditional Chinese herbal medicine, with improved bioavailability, and is widely used for malaria treatment. Recently, its potential effects on diabetic complications, particularly diabetic kidney disease (DKD), have attracted increasing attention. This study aimed to evaluate the therapeutic effects of Art on DKD and to explore the underlying mechanisms. Specifically, we investigated the protective role of Art against high glucose (HG)‐induced inflammatory biomarkers (transforming growth factor‐ β 1 [TGF‐ β 1], tumor necrosis factor‐ α [TNF‐ α ], interleukin‐1 β [IL‐1 β ], and interleukin‐6 [IL‐6]) and fibrosis in human renal proximal tubular epithelial (HK‐2) cells, focusing on the involvement of peroxisome proliferator‐activated receptor gamma (PPAR γ ) in DKD. To mimic diabetic conditions, HK‐2 cells were exposed to HG (30 mM) to induce inflammation and fibrosis. The therapeutic effects of Art (100 and 200 μ m) were assessed by immunofluorescence, real‐time RT‐PCR, and Western blot analyses. Our results demonstrated that Art effectively reversed the HG‐induced upregulation of inflammatory and fibrogenic markers in HK‐2 cells (∗ p < 0.05, ∗∗ p < 0.001, and ## p < 0.001). Additionally, Art pretreatment restored the HG‐suppressed expression of PPAR γ (∗ p < 0.05 and ## p < 0.001), suggesting that Art exerts its antifibrotic effects by modulating PPAR γ and inhibiting the TGF‐ β /Smad pathway. This hypothesis was further supported by siRNA‐mediated knockdown of PPAR γ , which significantly diminished Art′s antifibrotic effects (∗ p < 0.05, ∗∗ p < 0.001, and ## p < 0.001). In conclusion, our study indicates that Art protects renal tubular epithelial cells by partially modulating PPAR γ ‐dependent inhibition of the TGF‐ β /Smad pathway, thereby mitigating HG‐induced inflammation and fibrosis. These findings suggest that Art holds promising therapeutic potential for DKD treatment.
- Open Access
- 21 September 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 29 (35) , 5125-5137
Clinical characteristics and outcome of autoimmune pancreatitis based on serum immunoglobulin G4 level: A single-center, retrospective cohort study
Pancreatic ductal adenocarcinoma (PDAC) remains a significant public health challenge and is currently the fourth leading cause of cancer-related mortality in developed countries. Despite advances in cancer treatment, the 5-year survival rate for patients with PDAC remains less than 5%. In recent years, neoadjuvant therapy (NAT) has emerged as a promising treatment option for many cancer types, including locally advanced PDAC, with the potential to improve patient outcomes. To analyze the role of NAT in the setting of locally advanced PDAC over the past decade, a systematic literature search was conducted using PubMed and Web of Science. The results suggest that NAT may reduce the local mass size, promote tumor downstaging, and increase the likelihood of resection. These findings are supported by the latest evidence-based medical literature and the clinical experience of our center. Despite the potential benefits of NAT, there are still challenges that need to be addressed. One such challenge is the lack of consensus on the optimal timing and duration of NAT. Improved criteria for patient selection are needed to further identify PDAC patients likely to respond to NAT. In conclusion, NAT has emerged as a promising treatment option for locally advanced PDAC. However, further research is needed to optimize its use and to better understand the role of NAT in the management of this challenging disease. With continued advances in cancer treatment, there is hope of improving the outcomes of patients with PDAC in the future.
- 21 September 2023
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 29 (35) , 5125-5137
Open AccessClinical characteristics and outcome of autoimmune pancreatitis based on serum immunoglobulin G4 level: A single-center, retrospective cohort study
Pancreatic ductal adenocarcinoma (PDAC) remains a significant public health challenge and is currently the fourth leading cause of cancer-related mortality in developed countries. Despite advances in cancer treatment, the 5-year survival rate for patients with PDAC remains less than 5%. In recent years, neoadjuvant therapy (NAT) has emerged as a promising treatment option for many cancer types, including locally advanced PDAC, with the potential to improve patient outcomes. To analyze the role of NAT in the setting of locally advanced PDAC over the past decade, a systematic literature search was conducted using PubMed and Web of Science. The results suggest that NAT may reduce the local mass size, promote tumor downstaging, and increase the likelihood of resection. These findings are supported by the latest evidence-based medical literature and the clinical experience of our center. Despite the potential benefits of NAT, there are still challenges that need to be addressed. One such challenge is the lack of consensus on the optimal timing and duration of NAT. Improved criteria for patient selection are needed to further identify PDAC patients likely to respond to NAT. In conclusion, NAT has emerged as a promising treatment option for locally advanced PDAC. However, further research is needed to optimize its use and to better understand the role of NAT in the management of this challenging disease. With continued advances in cancer treatment, there is hope of improving the outcomes of patients with PDAC in the future.
- 6 October 2022
- Published by Elsevier in Nano Today
- Vol. 47, 101631
Ruxolitinib-loaded black phosphorus nanosheets actively target proximal tubule cells to ameliorate nephrotic syndrome by reducing inflammation and oxidative stress
- 6 October 2022
- Published by Elsevier in Nano Today
- Vol. 47, 101631
Ruxolitinib-loaded black phosphorus nanosheets actively target proximal tubule cells to ameliorate nephrotic syndrome by reducing inflammation and oxidative stress
- 23 July 2022
- Published by Springer Nature in Biological Trace Element Research
- Vol. 201 (5) , 2442-2457
ZnT8 Exerts Anti-apoptosis of Kidney Tubular Epithelial Cell in Diabetic Kidney Disease Through TNFAIP3-NF-κB Signal Pathways
Apoptosis of kidney tubular epithelial cells contributes to diabetic kidney disease (DKD) pathophysiology, but the mechanisms are not fully understood. Zinc transporter protein member 8 (ZnT8, SLC30A8) is a susceptive gene in diabetes. Here, we aim to investigate whether ZnT8 has effects on pathophysiology of DKD. The animal groups include control, ZnT8KO mice, STZ-induced, and ZnT8-KO-STZ. STZ-induced DKD was performed in male C57BL/6 J mice and in ZnT8-KO mice. High glucose (HG)–induced apoptosis in a normal rat kidney tubular epithelial cell line (NRK-52E cells) was performed in vitro. Transfection of hZnT8-EGFP or TNFAIP3 siRNA was done in NRK-52E cells. Flow cytometry with Annexin V-FITC/PI double staining and TUNEL analysis was performed for the detection of apoptosis. Gene expression at mRNA and protein levels was examined with real-time RT-PCR and Western blot. Urine albumin to creatinine ratio, proinflammatory cytokines, and apoptosis were enhanced in kidneys of STZ and ZnT8-KO-STZ mice compared to control or ZnT8-KO mice. ZnT8 overexpression after hZnT8-EGFP transfection decreased HG-stimulated inflammatory activity and apoptosis in NRK-52E cells. Furthermore, treatment with ZnSO4 blunted HG-induced apoptosis and NF-κB activation. ZnSO4 increased the abundance of zinc-finger protein TNF-α-induced protein 3 (TNFAIP3). Also, ZnT8 over-expression after hZnT8-EGFP transfection significantly ameliorates HG-induced NF-κB-dependent transcriptional activity and apoptotic protein expressions in NRK-52E cells, but the inhibitory effect of ZnT8 was significantly abolished with TNFAIP3 siRNA. Our study provides evidence that ZnT8 has protective effects against apoptosis of renal tubular epithelial cells through induction of TNFAIP3 and subsequent suppression of the NF-κB pathway.
- 23 July 2022
- Published by Springer Nature in Biological Trace Element Research
- Vol. 201 (5) , 2442-2457
ZnT8 Exerts Anti-apoptosis of Kidney Tubular Epithelial Cell in Diabetic Kidney Disease Through TNFAIP3-NF-κB Signal Pathways
Apoptosis of kidney tubular epithelial cells contributes to diabetic kidney disease (DKD) pathophysiology, but the mechanisms are not fully understood. Zinc transporter protein member 8 (ZnT8, SLC30A8) is a susceptive gene in diabetes. Here, we aim to investigate whether ZnT8 has effects on pathophysiology of DKD. The animal groups include control, ZnT8KO mice, STZ-induced, and ZnT8-KO-STZ. STZ-induced DKD was performed in male C57BL/6 J mice and in ZnT8-KO mice. High glucose (HG)–induced apoptosis in a normal rat kidney tubular epithelial cell line (NRK-52E cells) was performed in vitro. Transfection of hZnT8-EGFP or TNFAIP3 siRNA was done in NRK-52E cells. Flow cytometry with Annexin V-FITC/PI double staining and TUNEL analysis was performed for the detection of apoptosis. Gene expression at mRNA and protein levels was examined with real-time RT-PCR and Western blot. Urine albumin to creatinine ratio, proinflammatory cytokines, and apoptosis were enhanced in kidneys of STZ and ZnT8-KO-STZ mice compared to control or ZnT8-KO mice. ZnT8 overexpression after hZnT8-EGFP transfection decreased HG-stimulated inflammatory activity and apoptosis in NRK-52E cells. Furthermore, treatment with ZnSO4 blunted HG-induced apoptosis and NF-κB activation. ZnSO4 increased the abundance of zinc-finger protein TNF-α-induced protein 3 (TNFAIP3). Also, ZnT8 over-expression after hZnT8-EGFP transfection significantly ameliorates HG-induced NF-κB-dependent transcriptional activity and apoptotic protein expressions in NRK-52E cells, but the inhibitory effect of ZnT8 was significantly abolished with TNFAIP3 siRNA. Our study provides evidence that ZnT8 has protective effects against apoptosis of renal tubular epithelial cells through induction of TNFAIP3 and subsequent suppression of the NF-κB pathway.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1199: THE DENDRITIC CELL DNGR-1 PROTECTS AGAINST PERSISTENT ACINAR-TO-DUCTAL METAPLASIA AND INFLAMMATION BY LIMITING T-CELL IL-17 PRODUCTION
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1199: THE DENDRITIC CELL DNGR-1 PROTECTS AGAINST PERSISTENT ACINAR-TO-DUCTAL METAPLASIA AND INFLAMMATION BY LIMITING T-CELL IL-17 PRODUCTION
- Open Access
- 1 March 2021
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 14, 929-940
Effects of Curcumin on High Glucose-Induced Epithelial-to-Mesenchymal Transition in Renal Tubular Epithelial Cells Through the TLR4-NF-κB Signaling Pathway
Objective: Diabetic kidney disease (DKD) is a microvascular complication in diabetes mellitus, while tubuloepithelial to mesenchymal transition (EMT) of mature tubular epithelial cells is a key point in the early development and progression of renal interstitial fibrosis. The present study aimed to investigate the protective effects of Curcumin on EMT and fibrosis in cultured normal rat kidney tubular epithelial cell line (NRK-52E). Methods: By using immunofluorescence staining and Western blot protocols, in vitro experiments were designed to analyze EMT markers, including collagen I and E-cadherin in high glucose (HG) exposed NRK-52E cells and to detect the expression levels of phosphorylated-NF-κB, TLR4 and reactive oxygen species (ROS) after Curcumin pre-treatment. With co-treatment with TAK242, these molecules in the TLR4-NF-κB signaling pathway were further evaluated. Results: Curcumin decreased the HG-induced EMT levels and ROS production in NRK-52E cells. Furthermore, Curcumin was found to inhibit the TLR4-NF-κB signaling activation in HG-induced EMT of NRK-52E cells. Conclusion: The present study provides evidence suggesting a novel mechanism that Curcumin exerts the anti-fibrosis effects via inhibiting activation of the TLR4-NF-κB signal pathway and consequently protecting the HG-induced EMT in renal tubular epithelial cells. Thereby, TLR4-NF-κB may be a useful target for therapeutic intervention in DKD.
- 1 March 2021
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 14, 929-940
Open AccessEffects of Curcumin on High Glucose-Induced Epithelial-to-Mesenchymal Transition in Renal Tubular Epithelial Cells Through the TLR4-NF-κB Signaling Pathway
Objective: Diabetic kidney disease (DKD) is a microvascular complication in diabetes mellitus, while tubuloepithelial to mesenchymal transition (EMT) of mature tubular epithelial cells is a key point in the early development and progression of renal interstitial fibrosis. The present study aimed to investigate the protective effects of Curcumin on EMT and fibrosis in cultured normal rat kidney tubular epithelial cell line (NRK-52E). Methods: By using immunofluorescence staining and Western blot protocols, in vitro experiments were designed to analyze EMT markers, including collagen I and E-cadherin in high glucose (HG) exposed NRK-52E cells and to detect the expression levels of phosphorylated-NF-κB, TLR4 and reactive oxygen species (ROS) after Curcumin pre-treatment. With co-treatment with TAK242, these molecules in the TLR4-NF-κB signaling pathway were further evaluated. Results: Curcumin decreased the HG-induced EMT levels and ROS production in NRK-52E cells. Furthermore, Curcumin was found to inhibit the TLR4-NF-κB signaling activation in HG-induced EMT of NRK-52E cells. Conclusion: The present study provides evidence suggesting a novel mechanism that Curcumin exerts the anti-fibrosis effects via inhibiting activation of the TLR4-NF-κB signal pathway and consequently protecting the HG-induced EMT in renal tubular epithelial cells. Thereby, TLR4-NF-κB may be a useful target for therapeutic intervention in DKD.
- 1 February 2021
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 172, 108445
SLC30A7 has anti-oxidant stress effects in high glucose-induced apoptosis via the NFE2L2/HMOX1 signal transduction pathway
- 1 February 2021
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 172, 108445
SLC30A7 has anti-oxidant stress effects in high glucose-induced apoptosis via the NFE2L2/HMOX1 signal transduction pathway
- Open Access
- 17 July 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (7) , 1-13
Effects of ZnT8 on epithelial-to-mesenchymal transition and tubulointerstitial fibrosis in diabetic kidney disease
Zinc transporter 8 (ZnT8) transports zinc ions for crystallization and storage of insulin in pancreatic beta-cells and ZnT8 dysfunction is involved in pathogenesis of diabetes. The current study aimed to investigate whether ZnT8 has effects in pathophysiology of diabetic kidney disease (DKD) by using animal models for diabetes, including STZ-induced diabetic, db/db, ZnT8-KO, ZnT8-KO-STZ and ZnT8-KO-db/db mice. Results demonstrated that urine albumin to creatinine ratio and epithelial-to-mesenchymal transition (EMT) were increased in kidneys of ZnT8-KO-STZ and ZnT8-KO-db/db mice compared with C57BL/6 J and ZnT8-KO mice, while serum TGF-β1, IL-6, and TNF-α levels were elevated in parallel. In kidneys of mice intercrossed between ZnT8-KO and STZ-induced diabetic or db/db mice, these three inflammatory factors, ACR and EMT were also found to be increased compared with C57BL/6J, db/db and ZnT8-KO mice. Furthermore, ZnT8 up-regulation by hZnT8-EGFP reduced the levels of high glucose (HG)-induced EMT and inflammatory factors in normal rat kidney tubular epithelial cell (NRK-52E cells). Expression of phosphorylated Smad2/Smad3 was up-regulated after HG stimulation and further enhanced by ZnT8 siRNA but down-regulated after hZnT8-EGFP gene transfection. The current study thus provides the first evidence that ZnT8 protects against EMT-tubulointerstitial fibrosis though the restrain of TGF-β1/Smads signaling activation in DKD.
- 17 July 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (7) , 1-13
Open AccessEffects of ZnT8 on epithelial-to-mesenchymal transition and tubulointerstitial fibrosis in diabetic kidney disease
Zinc transporter 8 (ZnT8) transports zinc ions for crystallization and storage of insulin in pancreatic beta-cells and ZnT8 dysfunction is involved in pathogenesis of diabetes. The current study aimed to investigate whether ZnT8 has effects in pathophysiology of diabetic kidney disease (DKD) by using animal models for diabetes, including STZ-induced diabetic, db/db, ZnT8-KO, ZnT8-KO-STZ and ZnT8-KO-db/db mice. Results demonstrated that urine albumin to creatinine ratio and epithelial-to-mesenchymal transition (EMT) were increased in kidneys of ZnT8-KO-STZ and ZnT8-KO-db/db mice compared with C57BL/6 J and ZnT8-KO mice, while serum TGF-β1, IL-6, and TNF-α levels were elevated in parallel. In kidneys of mice intercrossed between ZnT8-KO and STZ-induced diabetic or db/db mice, these three inflammatory factors, ACR and EMT were also found to be increased compared with C57BL/6J, db/db and ZnT8-KO mice. Furthermore, ZnT8 up-regulation by hZnT8-EGFP reduced the levels of high glucose (HG)-induced EMT and inflammatory factors in normal rat kidney tubular epithelial cell (NRK-52E cells). Expression of phosphorylated Smad2/Smad3 was up-regulated after HG stimulation and further enhanced by ZnT8 siRNA but down-regulated after hZnT8-EGFP gene transfection. The current study thus provides the first evidence that ZnT8 protects against EMT-tubulointerstitial fibrosis though the restrain of TGF-β1/Smads signaling activation in DKD.